25G-NBOMe

25G-NBOMe
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
IUPAC name
  • 2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC20H27NO3
Molar mass329.4 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C(C=C(C(=C1C)OC)CCNCC2=CC=CC=C2OC)OC
InChI
  • InChI=1S/C20H27NO3/c1-14-15(2)20(24-5)16(12-19(14)23-4)10-11-21-13-17-8-6-7-9-18(17)22-3/h6-9,12,21H,10-11,13H2,1-5H3
  • Key:VDAUMFACIMNTDA-UHFFFAOYSA-N

25G-NBOMe (NBOMe-2C-G) is a derivative of the phenethylamine hallucinogen 2C-G, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1]

Legality

Sweden

The Riksdag added 25G-NBOMe to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of January 16, 2015, published by Medical Products Agency (MPA) in regulation LVFS 2014:11 listed as 25G-NBOMe, and 2-(2,5-dimetoxi-3,4-dimetylfenyl)-N-(2-metoxibensyl)etanamin.[2]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[3]

See also

References

  1. "Archived copy" (PDF). Archived from the original (PDF) on 2015-03-16. Retrieved 2017-04-21.{{cite web}}: CS1 maint: archived copy as title (link)
  2. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". www.legislation.gov.uk.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.